Skip to main content
. 2023 May 1;19(1):60–70. doi: 10.17925/EE.2023.19.1.60

Figure 4. Treatment schematic and design of phase II MGL-3196-05 (ClinicalTrials.gov identifier: NCT02912260) 36-week main and open-label extension studies Used with permission from ©Mount Sinai Health System.

Figure 4.

BL = baseline; OLE = open-label extension; PDFF = proton density fat fraction; W12 = week 12; W36 = week 36.